Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat

Molecular Brain Research

Volumn 47, Issue 1-2, 1997, Pages 311-321

  Salin, Pascal ^a   Dziewczapolski, Gustavo ^b   Gershanik, Oscar S ^b   Nieoullon, André ^a   Raisman Vozari, Rita ^c  

^a CNRS   (France)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Dopamine; L DOPA treatment; mRNA expression; Neostriatum; Neuropeptide

Indexed keywords

ANTIPARKINSON AGENT; BRAIN PROTEIN; ENKEPHALIN; LEVODOPA; MESSENGER RNA; OXIDOPAMINE; PREPROENKEPHALIN; PREPROTACHYKININ; SUBSTANCE P;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HISTOCHEMISTRY; NEOSTRIATUM; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ZONA INCERTA;

ANIMALS; CORPUS STRIATUM; ENKEPHALINS; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEVODOPA; OXIDOPAMINE; PROTEIN PRECURSORS; RATS; RATS, WISTAR; TACHYKININS; TIME FACTORS;

EID: 0031009082     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(97)00068-5     Document Type: Article

References (45)

1. Abercrombie, D.E., Bonatz, A.E. and Zigmond, M.J., MK-801 Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats, Brain Res., 525 (1990) 36-44.
2. Aria, R., Karasawa, N., Geffard, M. and Naghatsu, I., L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study, Neurosci. Lett., 195 (1995) 195-198.
3. Asin, K.E., Bednarz, L., Nikkel, A. and Perner, R., Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa, J. Pharm. Exp. Ther., 273 (1995) 1483-1490.
4. Bal, A., Savasta, M., Chritin, M., Mennicken F., Abrous, D.N., Le Moal, M., Feuerstein, C. and Herman, J.P., Transplantation of fetal nigral cells reverses the increase of preproenkephalin mRNA levels in the rat striatum caused by 6-OHDA lesion of the dopaminergic nigrostriatal pathway: a quantitative in situ hybridization study, Mol. Brain Res., 18 (1993) 221-227.
5. Blanchard, V., Christin, M., Vyas, S., Savasta, M., Feuerstein, C., Agid, Y., Javoy-Agid, F. and Raisman-Vozari, R., Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain, J. Neurochem., 64 (1995) 1669-1679.
6. Campbell, K. and Björklund, A., Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum, Eur. J. Neurosci., 6 (1994) 1371-1383.
7. Cenci, M.A., Campbell, K. and Björklund, A., Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin an, preprodynorphin messenger RNA levels, Neuroscience, 57 (1993) 275-296.
8. Cole, D.G., Growdon, J.H. and Di Figlia, M., Levodopa induction of fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra, Exp. Neurol., 120 (1993) 223-232.
9. Engber, T.M., Papa, S.M., Boldry, R. and Chase, T.N., NMDA receptor blockade reverses motor response alterations induced by levodopa, NeuroReport, 5 (1994) 2586-2588.
10. Engber, T.M., Susel, Z., Juncos, J.L. and Chase, T.N., Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists, Eur. J. Parm., 168 (1989) 291-298.
11. Engber, T.M., Susel, Z., Kuo, S. and Chase, T.N., Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization, J. Neurosci., 10 (1990) 3889-3895.
12. Engber, T.M., Susel, Z., Kuo, S., Gerfen, C.R. and Chase, T.N., Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats, Brain Res., 552 (1991) 113-118.
13. Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, Jr., F.J. and Sibley, D.R., D1 and D2 dopamine receptorregulated gene expression of striatonigral and striatopallidal neurons, Science, 250 (1990) 1429-1432.
14. Gerfen, C.R., Mc Ginty, J.F. and Young, W.S., Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis, J. Neurosci., 11 (1991) 1016-1031.
15. Gerfen, C.R. and Young, III, W.S., Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study, Brain Res., 460 (1988) 161-167.
16. Granata, R., Wenning, G.K., Jolkkonen, J., Jenner, P. and Marsden, C.D., Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion, J. Neural. Transm., 103 (1996) 249-260.
17. Greenamyre, J.T. and O'Brien, C.F., N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease, Ach. Neurol., 48 (1991) 977-981
18. Hajji, My. D., Salin, P. and Kerkerian Le Goff, L., Chronic dizocilpine maleate (MK-801) treatment suppresses the effects of nigrostriatal dopamine deafferentation on enkephalin but not substance P expression in the rat striatum, Eur. J. Neurosci., 8 (1996) 917-926.
19. Harden, D.G. and Grace, A.A., Activation of dopamine cell firing by repeated L-DOPA administration-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment, J. Neurosci., 15 (1995) 6157-6166.
20. Hefti, F., Melamed, E. and Wurtman, R.J., The site of dopamine formation in rat striatum after L-DOPA administration, J. Pharmacol. Exp. Ther., 217 (1981) 189-197.
21. Herrero, M.-T., Augood, S.J., Hirsch, E.C., Javoy-Agid, F., Luquin, M.R., Agid, Y., Obeso, J.A. and Emson, P.C., Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum, Neuroscience, 68 (1995) 1189-1198.
22. Howels, R.D., Kilpatrick, D.L., Bhatt, R., Monahan, J.J., Poonian, M. and Udenfriend, S., Molecular cloning and sequence determination of rat preproenkephalin cDNA: sensitive probe for studying transcriptional changes in rat tissues, Proc. Natl. Acad. Sci. USA, 81 (1984) 7651-7655.
23. Jolkkonen, J., Jenner, P. and Marsden, C.D., L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP, Mol. Brain Res., 32 (1995) 297-307.
24. 2 sites in rat caudate-putamen: localization to intrinsic neurons and not to neocortical afferents, Neuroscience, 20 (1987) 773-795.
25. König, J.H.R. and Klippel, R.A., The Rat Brain: A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem, Willams and Wilkins, Baltimore, MD, 1963.
26. Krause, J.E., Chirgwin, J.M., Carter, M.S., Xu, Z.S. and Hershey, A.D., Three rat preprotachykinin mRNAs encode the neuropeptides Substance P and Neurokinine A, Proc. Natl. Acad. Sci. USA, 84 (1987) 881-885
27. Le Moine, C. and Bloch, B., D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum, J. Comp. Neurol., 355 (1995) 418-426.
28. 2 receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis, J. Neurosci., 10 (1990) 2587-2600.
29. Marsden, C.D. and Parkes, J.D., Success and problems of long-term levodopa therapy in Parkinson's disease, Lancet, 1 (1977) 345-349.
30. Mendez, I.M., Naus, C.C.G., Elisevich, K. and Flumerfelt, B.A., Normalization of striatal proenkephalin and preprotachykinin mRNA expression by fetal substantia nigra grafts, Exp. Neurol., 119 (1993) 1-10.
31. Morelli, M., Cozzolino, A., Pinna, A., Fenu, S., Carta, A. and Di Chiara, G., L-DOPA stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors, Brain Res., 623 (1993) 334-336.
32. Morelli, M., Pinna, A., Fenu, S., Carta, A., Cozzolino, A. and Di Chiara, G., Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats, Synapse, 18 (1994) 288-293.
33. Nisenbaum, L.K., Crowley, W.R. and Kitai, S.T., Partial striatal dopamine depletion differentially affects striatal substance P and enkephalin messenger RNA expression, Mol. Brain Res., 37 (1996) 209-216.
34. Normand, E., Popovici, T., Onteniente, B., Fellmann, D., PiatierTonneau, D., Auffray, C. and Bloch, B., Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons, Brain Res., 439 (1988) 39-46.
35. Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, 2nd Ed., Academic Press, London, UK, 1986.
36. Salin, P., Hajji, My. D. and Kerkerian Le Goff, L., Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia, Eur. J. Neurosci., 8 (1996) 1746-1757.
37. +): reversal by embryonic nigral dopamine grafts, Mol. Brain Res., 9 (1991) 263-269.
38. Snyder-Keller, A.M., Striatal c-fos induction by drugs and stress in neonatally dopamine-depleted rats given nigral transplants: importance of NMDA activation and relevance to sensitization phenomena, Exp. Neurol., 113 (1991) 155-165.
39. Starr, M.S., Antiparkinsonian actions of glutamate antagonists -alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms, J. Neural. Transm. P-D Sect., 10 (1995) 141-185.
40. Taylor, M.D., De Ceballos, M.L., Rose, S., Jenner, P. and Marsden, C.D., Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydrophenylalanine treatment on peptidergic systems in rat basal ganglia, Eur. J. Pharm., 219 (1992) 183-192.
41. Trugman, J.M. and Wooten, G.F., The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra, Brain Res., 379 (1986) 264-274.
42. Trugman, J.M. and Wooten, G.F., Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions, J. Neurosci., 7 (1987) 2927-2935.
43. Weick, B.G., Engber, T.M., Susel, Z., Chase, T.N. and Walters, J.R., Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration, Brain Res., 523 (1990) 16-22.
44. Young, III, W.S., Bonner, T.I. and Brann, M.R., Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain, Proc. Natl. Acad. Sci. USA, 83 (1986) 9827-9831.
45. Zeng, B.-Y., Jolkkonen, J., Jenner, P. and Marsden, C.D., Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat, Neuroscience, 66 (1995) 19-28.